China is cracking down on fraud and corruption. Frequent fraudster GSK didn’t take this change in attitude seriously. The result, as highlighted by the New York Times, was a takedown of epic proportions.

| GSK, Fraud, China

GlaxoSmithKline: $3 Billion Settlement and a Big Wink

FCA | GSK, off-label marketing, pharmaceutical, criminal, civil